{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T06:25:13Z","timestamp":1766557513079,"version":"build-2065373602"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.clml.2014.10.001","type":"journal-article","created":{"date-parts":[[2014,10,24]],"date-time":"2014-10-24T02:40:38Z","timestamp":1414118438000},"page":"208-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Peripheral Blood Lymphocyte\/Monocyte Ratio Predicts Outcome in Follicular Lymphoma and in\u00a0Diffuse Large B-Cell Lymphoma Patients in\u00a0the\u00a0Rituximab Era"],"prefix":"10.1016","volume":"15","author":[{"given":"Angelo","family":"Belotti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisa","family":"Doni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvia","family":"Bolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Rossini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivana","family":"Casaroli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Pezzatti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrico Maria","family":"Pogliani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pietro Enrico","family":"Pioltelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2014.10.001_bib1","series-title":"SEER Cancer Statistics Review","first-page":"23","author":"National Cancer Institute","year":"2008"},{"key":"10.1016\/j.clml.2014.10.001_bib2","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin lymphomas: distribution of the major subtypes differ by geographic locations. Non-Hodgkin Lymphoma Classification Project","volume":"7","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.clml.2014.10.001_bib3","doi-asserted-by":"crossref","first-page":"S93","DOI":"10.1179\/102453312X13336169156014","article-title":"New developments in the management of diffuse large B-cell lymphoma","volume":"18","author":"Habermann","year":"2012","journal-title":"Hematology"},{"key":"10.1016\/j.clml.2014.10.001_bib4","first-page":"987","article-title":"A\u00a0predictive model for aggressive NHL: the International non-Hodgkin Lymphoma Prognostic Factors Project","volume":"329","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.10.001_bib5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large B-cell lymphoma","volume":"346","author":"Rosenwald","year":"2002","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.10.001_bib6","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Hans","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.10.001_bib7","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa0802885","article-title":"Stromal gene signatures in large-B-cell lymphomas","volume":"359","author":"Lenz","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.10.001_bib8","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1111\/j.1365-2559.2010.03706.x","article-title":"The challenge of the microenvironment in B-cell lymphomas","volume":"58","author":"Coupland","year":"2011","journal-title":"Histopathology"},{"key":"10.1016\/j.clml.2014.10.001_bib9","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.10.001_bib10","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Gutierrez-Garcia","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.10.001_bib11","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJM199309303291402","article-title":"A\u00a0predictive model for aggressive non-Hodgkin lymphoma. The International Non-Hodgkin Lymphoma Prognostic Factors Project","volume":"329","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.10.001_bib12","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International Prognostic Index remains a valid predictor of outcome for patients with aggressive CD20 B-cell lymphoma in the rituximab era","volume":"28","author":"Ziepert","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib13","doi-asserted-by":"crossref","first-page":"3424","DOI":"10.1172\/JCI63186","article-title":"Pathogenesis of follicular lymphoma","volume":"122","author":"Kridel","year":"2012","journal-title":"J\u00a0Clin Invest"},{"key":"10.1016\/j.clml.2014.10.001_bib14","doi-asserted-by":"crossref","first-page":"3659","DOI":"10.1182\/blood-2011-11-367730","article-title":"Follicular lymphoma and the immune system: from pathogenesis to antibody therapy","volume":"119","author":"Stevenson","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.10.001_bib15","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib16","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.10.001_bib17","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma International Prognostic Index 2: a new prognostic index for follicular lymphoma developed by the International Follicular Lymphoma Prognostic Factor Project","volume":"27","author":"Federico","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib18","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1200\/JCO.2010.33.4474","article-title":"Watchful waiting in low\u2013tumor burden follicular lymphoma in the rituximab era: results of an F2-study database","volume":"30","author":"Solal-Celigny","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib19","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1038\/leu.2011.112","article-title":"The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma","volume":"25","author":"Wilcox","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2014.10.001_bib20","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkin lymphoma","volume":"362","author":"Steidl","year":"2010","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.clml.2014.10.001_bib21","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1200\/JCO.2010.32.8401","article-title":"Molecular pathogenesis of Hodgkin lymphoma: increasing evidence of the importance of the microenvironment","volume":"29","author":"Steidl","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib22","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1189\/jlb.0706481","article-title":"Critical role of monocytes to support normal B cell and diffuse large B-cell lymphoma survival and proliferation","volume":"82","author":"Mueller","year":"2007","journal-title":"J\u00a0Leukoc Biol"},{"key":"10.1016\/j.clml.2014.10.001_bib23","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.1365-2141.2007.06596.x","article-title":"Absolute lymphocyte count predicts therapeutic efficacy of rituximab therapy in follicular lymphomas","volume":"137","author":"Behl","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.10.001_bib24","first-page":"e4165","article-title":"Blood lymphocyte-to-monocyte ratio identifies high-risk patients in diffuse large B-cell lymphoma treated with R-CHOP","volume":"7","author":"Li","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.clml.2014.10.001_bib25","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/j.1365-2141.2006.06232.x","article-title":"Absolute lymphocyte count predicts overall survival in follicular lymphomas","volume":"134","author":"Siddiqui","year":"2006","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.10.001_bib26","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait\u00a0policy versus immediate systemic treatment for asymptomatic advanced-stage\u00a0non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2014.10.001_bib27","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1111\/j.1365-2141.2012.09067.x","article-title":"Peripheral blood lymphocyte\/monocyte ratio at diagnosis and survival in nodular lymphocyte-predominant Hodgkin lymphoma","volume":"157","author":"Porrata","year":"2012","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2014.10.001_bib29","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1002\/ajh.23566","article-title":"The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy","volume":"88","author":"Rambaldi","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2014.10.001_bib30","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1111\/ejh.12221","article-title":"Peripheral blood absolute lymphocyte\/monocyte ratio as a useful prognostic factor in diffuse large B-cell lymphoma in the rituximab era","volume":"92","author":"Watanabe","year":"2014","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.10.001_bib31","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2010-05-283820","article-title":"Immunosuppressive CD14+HLA-DR(low)\/\u2212 monocytes in B-cell non-Hodgkin lymphoma","volume":"117","author":"Lin","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2014.10.001_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s00277-013-1916-9","article-title":"Peripheral blood lymphocyte\/monocyte ratio predicts outcome for patients with diffuse large B cell lymphoma after standard first-line regimens","volume":"93","author":"Li","year":"2014","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2014.10.001_bib33","doi-asserted-by":"crossref","first-page":"135","DOI":"10.3324\/haematol.2008.001628","article-title":"Anti-CD20 monoclonal antibodies: historical and future perspectives","volume":"95","author":"Lim","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2014.10.001_bib34","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.clml.2014.10.001_bib35","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/annonc\/mds177","article-title":"Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up","volume":"23","author":"Colombat","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib36","doi-asserted-by":"crossref","first-page":"4480","DOI":"10.1200\/JCO.2010.28.4786","article-title":"Long-term follow-up of patients with follicular lymphoma receiving single-agent rituximab at two different schedules in trial SAKK 35\/98","volume":"28","author":"Martinelli","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib37","doi-asserted-by":"crossref","first-page":"3781","DOI":"10.1200\/JCO.2012.43.6584","article-title":"Waiting is the hardest part","volume":"30","author":"Cheson","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2014.10.001_bib38","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1111\/j.1600-0609.2008.01129.x","article-title":"Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab","volume":"81","author":"Oki","year":"2008","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.clml.2014.10.001_bib39","unstructured":"Sacchi S, Marcheselli L, Bari A, et\u00a0al. Absolute Monocyte and Lymphocyte Count in Follicular Lymphoma: Prognostic Role in Survival Outcome Evaluation. ABSSUB-4266; EHA.\u00a02015."},{"key":"10.1016\/j.clml.2014.10.001_bib40","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.leukres.2013.07.015","article-title":"Absolute monocyte count in follicular lymphoma patients treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"37","author":"Watanabe","year":"2013","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2014.10.001_bib41","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s12185-014-1576-0","article-title":"Ratio of peripheral blood absolute lymphocyte count to absolute monocyte count at diagnosis is associated with progression-free survival in follicular lymphoma","volume":"99","author":"Kumagai","year":"2014","journal-title":"Int J Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501400439X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S215226501400439X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:26:43Z","timestamp":1761870403000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S215226501400439X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S215226501400439X"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2014.10.001","relation":{},"ISSN":["2152-2650"],"issn-type":[{"type":"print","value":"2152-2650"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral Blood Lymphocyte\/Monocyte Ratio Predicts Outcome in Follicular Lymphoma and in\u00a0Diffuse Large B-Cell Lymphoma Patients in\u00a0the\u00a0Rituximab Era","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2014.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}